“The majority of meetings should be discussions that lead to decisions.” – Patrick Lencioni“People who enjoy meetings should not be in charge of anything.” – Thomas SowellThis month — it being springtime and all — let’s discuss the concept of practice …
Experts weigh current, future options for AMD management
The past 2 years have brought a decisive leap forward in the management of age-related macular degeneration.Pharmacotherapies with increased efficacy and extended durability are allowing for more relaxed treatment schedules, and for the first time, tre…
Advancements continue in development of retinal disease treatments
An intravitreal injection is now the most common surgical procedure performed in the United States by an ophthalmologist.In some countries, intravitreal injections are performed in a hospital-based surgery suite or ASC. In the U.S., the vast majority a…
Phase 2 nonproliferative diabetic retinopathy trial misses primary endpoint
SEATTLE — The phase 2 PAVIA trial investigating Duravyu, previously known as EYP-1901, for the treatment of nonproliferative diabetic retinopathy did not meet its primary endpoint, according to a press release from EyePoint Pharmaceuticals.“Although th…
Eye2Gene and Heidelberg Engineering Announce Collaborative Partnership at ARVO 2024
SEATTLE–(BUSINESS WIRE)–Eye2Gene™, a pioneering artificial intelligence National Institute for Health and Care Research (NIHR) funded project based at the University College London Institute of Ophthalmology and Moorfields Eye Hospital, and Heidelber…
Baxter Declares Quarterly Dividend
DEERFIELD, Ill.–(BUSINESS WIRE)–Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on July 1, 2…